← Eichor
Study identifier: NCT07114055 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome

Condition: Irritable Bowel Syndrome - Diarrhoea  ·  Sponsor: Md. Hazrat Ali

PhasePhase 2/Phase 3
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to assess and compare the effect of ebastine and placebo in improving symptoms in patients with diarrhea predominant IBS. It will also assess about the safety of drugs ebastine and placebo by recording the patient reported adverse events. The main questions it aim to answer are: Does drug ebastine and placebo has any effect on patients with IBS-D? What medical problems do participants have when taking drug ebastine and placebo? Researcher will compare effect of drug ebastine and placebo . Participant will: Take drug ebastine 20 mg at night and placebo once daily at night every day for 8 weeks along with lifestyle modifications. After that all two groups will visit the hospital 4 weekly, and their symptoms will be assessed by IBS symptom severity score (IBS-SSS) at baseline, week 4 and week 8. Additionally, patient reported adverse events will be documented.

This description comes directly from the study's public registry record.

Talk to the study team

Md. Hazrat Ali, MBBS  ·  +8801710725424  ·  mhalirmc45@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Dhaka Medical CollegeDhaka, BangladeshRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07114055